We searched Medline (2000–13) using the search term “liver cirrhosis”. We largely selected publications from the past 5 years, but we did not exclude highly relevant older publications. We selected further relevant publications from the reference lists of articles identified by this search strategy. Review articles and book chapters are cited to provide more details and references than can be cited here.
SeminarLiver cirrhosis
Introduction
Cirrhosis results from different mechanisms of liver injury that lead to necroinflammation and fibrogenesis; histologically it is characterised by diffuse nodular regeneration surrounded by dense fibrotic septa with subsequent parenchymal extinction and collapse of liver structures, together causing pronounced distortion of hepatic vascular architecture.1, 2 This distortion results in increased resistance to portal blood flow and hence in portal hypertension and in hepatic synthetic dysfunction. Clinically, cirrhosis has been regarded as an end-stage disease that invariably leads to death, unless liver transplantation is done, and the only preventive strategies have been screening for oesophageal varices and hepatocellular carcinoma.
Lately, this perception has been challenged, because 1-year mortality in cirrhosis varies widely, from 1% to 57%, depending on the occurrence of clinical decompensating events.3 Histopathologists have proposed that the histological term cirrhosis should be substituted by advanced liver disease, to underline the dynamic processes and variable prognosis of the disorder.4 Moreover, fibrosis, even in the cirrhotic range, regresses with specific therapy if available, such as antiviral treatment for chronic hepatitis B5 or C.6
Here, we review the current understanding of cirrhosis as a dynamic process and outline current therapeutic options for prevention and treatment of complications of cirrhosis, on the basis of the subclassification in clinical prognostic stages.3, 7 The new concept in management of patients with cirrhosis is the use of non-specific therapies for prevention and early intervention to stabilise disease progression and to avoid or delay decompensation and the need for liver transplantation.
Section snippets
Epidemiology
Cirrhosis is an increasing cause of morbidity and mortality in more developed countries. It is the 14th most common cause of death in adults worldwide but the fourth in central Europe; it results in 1·03 million deaths per year worldwide,8 170 000 per year in Europe,9 and 33 539 per year in the USA.10 Cirrhosis is the main indication for 5500 liver transplants each year in Europe.9 The main causes in more developed countries are infection with hepatitis C virus, alcohol misuse, and,
Pathophysiology
The transition from chronic liver disease to cirrhosis involves inflammation, activation of hepatic stellate cells with ensuing fibrogenesis, angiogenesis, and parenchymal extinction lesions caused by vascular occlusion.11 This process leads to pronounced hepatic microvascular changes, characterised by sinusoidal remodelling (extracellular matrix deposition from proliferating activated stellate cells resulting in capillarisation of hepatic sinusoids), formation of intrahepatic shunts (due to
Diagnosis
Most chronic liver disease is notoriously asymptomatic until cirrhosis with clinical decompensation occurs. Decompensating events include ascites, sepsis, variceal bleeding, encephalopathy, and non-obstructive jaundice. Imaging by ultrasonography, CT, or MRI of an irregular and nodular liver together with impaired liver synthetic function is sufficient for the diagnosis of cirrhosis. Other findings include small and shrunken liver, splenomegaly, and evidence of portosystemic collaterals.
Natural course
Cirrhosis should no longer be regarded as a terminal disease and the concept of a dynamic process is increasingly accepted. A prognostic clinical subclassification with four distinct stages has been proposed with substantially differing likelihoods of mortality: stage 1 (compensated with no oesophageal varices) has an estimated mortality of 1% per year, and stages 2 (compensated with varices), 3 (decompensated with ascites), and 4 (decompensated with gastrointestinal bleeding) have annual
Prevention and treatment of complications
The focus of this Seminar is on prevention and therapy in the initial stages of cirrhosis, including the first decompensating event.
Future therapies
Currently licensed drugs, such as non-selective β blockers, statins, oral antibiotics, and anticoagulants are likely to be used in various combinations to prevent and treat complications of cirrhosis in the near future.42, 132 Statins reduce HVPG and are associated with reduced incidence of hepatocellular carcinoma. Anticoagulation used to be considered a contraindication in cirrhosis; however, stable cirrhosis is characterised by normal thrombin generation and even hypercoagulability.133
Conclusions—future directions
Cirrhosis should no longer be considered as a single disease stage, because it has distinct clinical prognostic stages with substantial differences in 1-year survival.7 Preventive and therapeutic strategies are summarised in figure 5. Clinicians should try to diagnose advanced liver disease as early as possible and to prevent the progression to further clinical stages and the advent of complications. We have previously reviewed the potential expansion of current indications of widely used drugs
Search strategy and selection criteria
References (140)
- et al.
Liver cirrhosis
Lancet
(2008) - et al.
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies
J Hepatol
(2006) - et al.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Lancet
(2013) - et al.
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Lancet
(2012) - et al.
The burden of liver disease in Europe: a review of available epidemiological data
J Hepatol
(2013) - et al.
Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension
Hepatology
(1995) - et al.
Angiogenesis in liver disease
J Hepatol
(2009) - et al.
Functional aspects on the pathophysiology of portal hypertension in cirrhosis
J Hepatol
(2012) - et al.
Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis
Gastroenterology
(2010) - et al.
Renal failure and cirrhosis: a systematic review of mortality and prognosis
J Hepatol
(2012)